
    
      This was a European,multicenter,observational study of participants who were previously
      treated with pioglitazone or placebo in addition to their existing anti diabetic medication.
      This 10-year observational study was conducted as a follow-up of PROactive study
      (NCT00174993) to investigate the CV and macrovascular effects observed with pioglitazone over
      time during PROactive.In this study,high risk T2DM patients previously enrolled in PROactive
      were analyzed for long-term incidence,nature, and pattern of all malignancies in pioglitazone
      and placebo-treated groups.This study enrolled 3599 participants.No treatment was prescribed
      by this protocol and participants will be managed in accordance with normal medical
      practice.The planned total duration of the study was 10 years,with data being analyzed and
      reported every 2 years.Participants were assessed at nominal visits every 6 months and every
      effort was made to obtain as much of the required information as possible.
    
  